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A prospective pilot study of partial breast irradiation (PBI) with conventional vs hypofractionated
schedules was set out. The study aimed to determine efﬁcacy, acute and late side effects, and the
preference of photon vs electron irradiation based on individual features. Patients were enrolled
according to internationally accepted guidelines on PBI. Conformal radiotherapy plans were generated
with both photon and electron beams, and the preferred technique based on dose homogeneity and the
radiation exposure of healthy tissues was applied. For electron dose veriﬁcation, a special phantom was
constructed. Patients were randomized for fractionation schedules of 25  2 vs 13  3 Gy. Skin and breast
changes were registered at the time of and Z1 year after the completion of radiotherapy. Dose
homogeneity was better with photons. If the tumor bed was located in the inner quadrants, electron
beam gave superior results regarding conformity and sparing of organ at risk (OAR). If the tumor was
situated in the lateral quadrants, conformity was better with photons. A depth of the tumor bed
Z3.0 cm predicted the superiority of photon irradiation (odds ratio [OR] ¼ 23.6, 95% CI: 5.2 to 107.5,
p o 0.001) with 490% sensitivity and speciﬁcity. After a median follow-up of 39 months, among 72
irradiated cases, 1 local relapse out of the tumor bed was detected. Acute radiodermatitis of grade I to II,
hyperpigmentation, and telangiectasia developed Z1 year after radiotherapy, exclusively after electron
beam radiotherapy. The choice of electrons or photons for PBI should be based on tumor bed location;
the used methods are efﬁcient and feasible.
& 2015 American Association of Medical Dosimetrists.Introduction
Radiotherapy is an integral part of breast-conserving surgery,
which lowers the risk of both local recurrence and breast cancer-
related death.1 In low-risk breast cancer, accelerated partial breast
radiotherapy (APBI) is widely practiced and is an equally efﬁcient
alternative to whole-breast radiotherapy (WBI).2-4 Guidelines for
patient selection have been reported by the American Society for
Radiation Oncology and the Groupe Européen de Curiethérapie-
European Society for Therapeutic Radiology and Oncology,5,6
although a trend toward widening eligibility criteria is seen.2,3,7
There are multiple delivery methods for APBI, such as intra-
operative radiotherapy, intracavitary/interstitial brachytherapy,
and external beam radiotherapy.3 Regarding effectiveness, simi-
larly low ipsilateral recurrence rates are reported with the 3 meth-
ods. However, there is controversy regarding cosmetic outcome
after teletherapy, which is probably related to technical details.8f Medical Dosimetrists
2, H-6720 Szeged, Hungary.Although robust and long-term experiences were collected with
brachytherapy and intraoperative radiotherapy, as the access to
these methods is limited, the use of external beam radiotherapy is
increasing. For teletherapy, both conformal radiotherapy (CRT) and
intensity-modulated radiotherapy (IMRT) have been used2,3,6,8,9;
the advantages, as compared with brachytherapy, are noninvasiv-
ity, wide availability, and cost efﬁciency. A potential advantage of
CRT in terms of cosmetic outcome (clearly adversely affected by
skin or subcutaneus ﬁbrosis, skin atrophy, discoloration, and
telangiectasia) could be the more homogeneous dose distribution
as compared with that with brachytherapy.10 Besides having less
and shorter experience, additional disadvantages of CRT are the
lack of optimal fractionation schedule and the greater dose to the
organs at risk (OARs) including uninvolved tissue of the target
breast.3 Dose homogeneity is even better with IMRT than with
CRT.11 IMRT was expected to improve cosmetic outcome and to
further decrease OAR exposure. Nevertheless, some trials gave
negative results.12-15 The study by Jagsi et al.12 was prematurely
terminated because 7 of 32 patients showed unacceptable cos-
metic results 2.5 years after deep inspiration breath-hold IMRT,
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reported that, at a median follow-up of 15 months following CRT, 25%
of the patients showed moderate to severe and 8.3% showed severe
subcutaneous ﬁbrosis. In the large Randomized Trial of Accelerated
Partial Breast Irradiation (RAPID) clinical trial, after CRT APBI, signiﬁ-
cantly poorer cosmetic outcome was reported owing to late radiation
toxicity, than in the WBI arm.15 In contrast, based on the interim
results of another similar large prospective randomized trial, the
NSABP B39/RTOG 0413 study, no safety issue emerged.16 Then,
2 prospective8,9 and 1 retrospective17 IMRT studies indicated excellent
efﬁcacy and cosmetic outcome. The head-to-head comparison of CRT
(poorer dose homogeneity but less irradiated healthy tissue overall)
and IMRT (superior dose homogeneity but more healthy tissue
irradiated with low doses), with special regard to skin changes and
breast ﬁbrosis determining cosmetic results, is still awaited.
There is a need to provide partial breast irradiation (PBI) on a
routine basis to an increasing number of patients with low-risk
breast cancer, even in places with limited technical background. In
this pilot study, we aimed at prospectively investigating the
feasibility of PBI using photon vs electron irradiation with conven-
tional vs accelerated schedules. As previously no experience had
been gained with hypofractionated breast radiotherapy, we tested
the feasibility of 3-Gy fraction dose irradiation (either with photon
or electron beams) to the relatively small PBI breast volumes, in
comparison with the conventional fractionation schedule. Besides
the analysis of efﬁcacy and acute and late side effects, we intended
to ﬁnd out which parameters could predict the preference of
electron over photon irradiation in everyday practice.Methods and Materials
The study was approved by the Institutional Review Board of the University of
Szeged. All participants gave their written informed consent. Patients after breast-
conserving surgery were eligible if they were 450 years of age, had unifocal
carcinoma not larger than 30 mm of nonlobular histologic type, had node-negative
disease, had absence of extensive intraductal component (EIC) or in situ ductal
cancer (DCIS), had lymphovascular invasion, had surgical margin Z2 mm, or had
surgical clips present for the identiﬁcation of the tumor bed. In addition, the
situation of the tumor bed within the breast and the adjuvant systemic therapy
given according to the institutional guidelines were registered. Patients were
checked at the time of the radiotherapy, 3 months after completion, and every
6 months thereafter. Skin or breast changes were evaluated on the ﬁrst and the last
day of the radiotherapy and Z1 year thereafter according to the Common
Terminology Criteria for Adverse Events (CTC AE) vs 3.0 system.Fig. 1. Polymethyl methacrylate (PMMA) slab phantom (with incorporated metal and
veriﬁcation of electron dose calculations. (Color version of ﬁgure is available online.)Radiotherapy techniques
Computed tomography-based 3-dimensional treatment planning (Oncentra
Masterplans v4.3, Nucletron) and CRT were performed in all cases with the
patient in the supine position. All relevant technical details about patient position-
ing, immobilization, and imaging have been published previously.18 The target
volumes were contoured on the computed tomography slices in the radiotherapy
planning system by placing a 1-cm margin around the surgical cavity as deﬁned by
the surgical clips (clinical target volume), and using a 0.5-cm planning target volume
(PTV) margin, but excluding the chest wall and the tissue 4 mm under the skin.19 The
OARs were contoured as previously described20; the part of the operated breast
excluding the PTV was indicated as “ipsilateral breast.” The size of the PTV and the
distance of its geometric center beneath the skin (D) were recorded. The D was
measured in the radiotherapy planning system by deﬁning a simple isocentric
photon beam to the center of the PTV, and setting up the gantry angle perpendicular
to the surface. The D was 100 cm minus the focus-skin distance. The patients were
randomized to receive a mean dose to the PTV of either 25  2 or 13  3 Gy. Both
electron and photon plans were generated, and the choice of radiotherapy technique
was based on dose distribution in the PTV and OAR exposure.
Photon beams: In total, two 6- or 15-MV photon ﬁelds were used with a
physical wedge of 301 conformed to the PTV with a 58-leaf multileaf collimator.
Occasionally, 1 additional segment was used for better dose homogeneity. The dose
calculation was performed by the collapsed cone algorithm.
Electron beams: Overall, 6-, 9-, 12-, or 15-MeV (occasionally mixed) electron
beams using an applicator of 10  10 cm and rectangular inserts (6  6 cm, 6 
8 cm, etc.) were applied. The dose calculation was performed by the Voxel Monte
Carlo algorithm.
For the analysis of 3-dimensional dose distribution, the volume of the PTV
receiving 95% to 107% of the prescibed dose (V95% to V107%), and the doses received
by 5% and 95% of the PTV (D5%/D95%) were registered; the healthy tissue conformity
index (HTCI) and the conformation number (CN) were calculated using the
following equations: HTCI ¼ TVRIVRI and CN ¼
TVRI
TV  TVRIVRI (TV is target volume, i.e.,
PTV; TVPD is target volume covered by the prescribed dose; and VPD is volume of
the prescribed dose).20,21 For comparison, the relative doses to the OARs were
recorded as follows: the volumes of the ipsilateral breast receiving 4100%, 50%,
and 25% of the prescribed dose (V100% breast, V50% breast, and V25% breast); the volume
of the ipsilateral lung receiving440% of the prescribed dose (V40% lung); the volume
of the heart receiving450% of the prescribed dose (V50% heart, left-sided cases); the
volume of the left anterior descendent (LAD) receiving 420% of the prescribed
dose (V20% LAD, left-sided cases); and the volume of the contralateral breast
receiving 410% of the prescribed dose (V10% opp breast).
The radiotherapy was delivered with a Siemens Primus linear accelerator in
5 fractions per week.Veriﬁcation of the dose calculation for electron beams
Besides routine physical quality-control measurements, for electron dose
veriﬁcation, a special phantom was constructed, which simulated the anatomic
situation with respect to the curved surface and the structures with signiﬁcantly
different densities near the target volume.22 Disk-shaped aluminum and cork
pieces of 5  1 cm have been inserted into a poly(methyl methacrylate) slabair-equivalent compartments) and its schematic presentation, constructed for the
Table 1
Patient characteristics (n ¼ 72)
Age (mean  SE, y) 61.3  0.9
Premenopausal 8 (11.1%)
Menopausal 64 (88.9%)
Pathologic tumor size (pT) (mean  SE, mm) 11.5  0.5
Invasive ductal carcinoma not special type 63 (87.5%)
Tubular carcinoma 3 (4.2%)
Mucinous carcinoma 2 (2.7%)
Medullary carcinoma 1 (1.4%)
Papillary carcinoma 1 (1.4%)
Mixed carcinoma 1 (1.4%)
Cribriform carcinoma 1 (1.4%)
Grade I 27 (37.5%)
Grade II 34 (47.2%)
Grade III 11 (15.3%)
Hormone receptor positive 62 (86.1%)
Hormone receptor negative 10 (13.9%)
HER2 negative 70 (97.2%)
HER2 positive 2 (2.8%)
Surgical margin (mean  SE, mm) 7.30.5
Tumor location: inner quadrants 33 (45.8%)
Tumor location: outer quadrants 39 (54.2%)
Adjuvant hormone therapy
Aromatase inhibitor 9 (12.5%)
Tamoxifen 7 (9.7%)
Adjuvant chemotherapy 3 (4.1%)
SE ¼ standard error.
Fig. 2. Consort diagram of patients randomized to different treatment arms.
G. Fekete et al. / Medical Dosimetry 40 (2015) 290–295292phantomwith the proximal interface positioned at the depth of the maximum dose
(1.2 cm for the used 6-MeV electron beam) (Fig. 1). Computed tomography scans of
this phantom were acquired with a slice thickness of 1 mm. Dose distribution was
measured with Kodak EDR2 ﬁlm in both the homogeneous and inhomogeneous
cases, for normal and oblique beam incidence. Measured and calculated relative
dose distributions agreed o1% in all cases. The agreement between the calculated
and measured absorbed doses in the proximal interface was within 2.5% for both
aluminum and cork, with values decreasing within the accuracy threshold of ﬁlm
dosimetry method if applied for absolute dose estimation. Monitor unit calcu-
lations were in o2% difference range. Thus, the Voxel Monte Carlo algorithm was
found highly accurate in such a complex anatomic situation as breast radiotherapy.
Statistical methods
The differences of dose homogeneity, conformity index, and the dose-volume
parameters of the OARs between the 2 irradiation techniques were examined by
paired sample t-test. The associations between the various dosimetric data and the
geography and the depth of the tumor bed or the irradiation technique were
examined with paired sample t-tests. The incidence of acute and late toxicity was
analyzed by χ2 test. For testing the association between the depth of the tumor bed
and dose homogeneity index, correlation-regression analysis was done. To deﬁne
the cutoff point for D and to choose the electron irradiation technique, receiver
operating characteristics analysis was applied. Logistic regression models were
applied to examine the potential predictors for beam selection. First, binary
univariate logistic regression models were used separately, followed by the multi-
variate logistic regression model to examine the joint effects and interactions. A
stepwise procedure was employed with a likelihood ratio test. SPSS version 20.0 for
Windows (SPSS Inc., Chicago, IL) was applied for statistical analysis.Results and Discussion
Radiotherapy data
Between November 2009 and December 2012, 72 patients were
enrolled, all qualiﬁed for the inclusion criteria (Table 1). Most of
the cases (79.2%) had sentinel lymph node biopsy.
The number of the fractionation schedules and chosen radio-
therapy techniques are shown in Fig. 2. Electron beams were
applied in more than half of the cases. The mean  standard error
of the PTV volume was 87.4  5.8 cm3 (36 to 308 cm3) (inner vsouter quadrants: 74.9 vs 98.1 cm3, respectively, p ¼ 0.043). The
mean  standard error of D was 3.1  0.2 cm (1.0 to 7.0 cm) (inner
quadrants: 2.1 0.1 cm, outer quadrants: 4.0 0.2 cm, po 0.001).
The used radiotherapy technique was selected primarily by dose
distribution, and the dose to the OARs was checked thereafter.
Typical ﬁeld arrangements and dose distributions are shown in
Fig. 3.
Dose distribution and OAR exposure were primarily deter-
mined by the location of the tumor bed (Tables 2 and 3). If the
tumor was located in the inner quadrants, although the dose
homogeneity was somewhat better with photon beams, the
degree of conformity appeared similar regardless of beam quality
(electron vs photon). In contrast, if the tumor was excised from the
outer quadrants, the photon plans were superior in terms of both
dose homogeneity and conformity indices. In the inner-quadrant
cases, the radiation exposure of the ipsilateral and the contrala-
teral breast was more favorable with electron beams; however, no
such differences existed for the lung and the LAD (Table 3). In the
outer-quadrant cases, although the dose to the heart and the LAD
was similar, the V100% breast was signiﬁcantly higher if electron
irradiation was used; nonetheless, the V40% lung, the V25% breast, and
V50% breast were superior with electrons (Table 3). Regarding the
association between dose homogeneity (V95% to V107%) and the D, a
strong positive correlation existed if photon beams were used (R ¼
0.622, p o 0.001), and a strong negative correlation existed if
electron (R ¼  0.875, po 0.001) beams were used. Notably, using
electrons, the V95% to V107% was unacceptably low if D was
Z 3.0 cm (as provided by receiver operating characteristic curve
analysis); using this cutoff value, the sensitivity and speciﬁcity of
the prediction were 92.3% and 90.9%, respectively.
Consequently, the tumor location, the size of the PTV, and the D
were ﬁrst studied in binary univariate logistic regression models.
Signiﬁcant positive associations were found between the superi-
ority of electron over photon irradiation and the situation of the
tumor bed to the inner quadrants (odds ratio [OR] ¼ 33.3, 95% CI:
8.2 to 135.3, p o 0.001), a smaller D (OR ¼ 23.6, 95% CI: 5.2 to
107.5, po 0.001), and a smaller size of the PTV (OR ¼ 1.02, 95% CI:
1.0 to 1.03, p ¼ 0.01). The joint effects of the quadrant, the PTV, and
the D were examined in a multiple logistic regression model using
a stepwise algorithm. Only the D remained signiﬁcant in the
model.
Fig. 3. Typical ﬁeld arrangements and dose distributions for the irradiation of tumor beds in the inner or the outer quadrants of the breast; DVH shows dose homogeneity
within the target volume and the doses to selected OARs. a, a single 9MeV electron ﬁeld is used to cover the tumor bed in the upper-inner breast quadrant; b, 6 MV photon
ﬁelds are applied to irradiate the tumor bed in the outer-upper quadrant of the left breast. (Color version of ﬁgure is available online.)
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After a median follow-up time of 38.8 (5.6 to 45.3) months,
1 patient in the 25  2 Gy photon arm developed an in-breast
relapse outside of the tumor bed, and 1 sentinel node-negative
patient was diagnosed with axillary node metastasis. A patient
developed and died because of distant metastases. In addition, 2
other patients died owing to other causes than breast cancer.Table 2
Dose homogeneity and conformity indices according to tumor bed localization (inner v
V95% to V107% (%) (higher is better) D5%/D95% (lowe
Inner quadrants (n ¼ 33)
Electron 88.7  1.6 1.17  0.02
Photon 90.0  0.6 1.12  0.01
p 0.462 0.024
Outer quadrants (n ¼ 39)
Electron 54.4  4.6 2.96  0.75
Photon 93.7  1.8 1.07  0.05
p o 0.001 0.015Skin and breast changes according to the type of radiotherapy
and fractionation schedule are shown in Table 4. Acute radio-
dermatitis was more frequent in patients in the electron arms;
hyperpigmentation and teleangiectasia developed exclusively in
the electron-irradiated patients 41 year after the radiotherapy, in
10% and 17% of the cases, in the 25  2 Gy and 13  3 Gy arms,
respectively. A single case of subcutaneous/breast ﬁbrosis was
detected in the 13  3 Gy photon radiotherapy arm. Breast pains outer quadrant)
r is better) HTCI (higher is better) CN (higher is better)
0.82  0.03 0.43  0.01
0.79  0.02 0.42  0.01
0.159 0.694
0.49  0.03 0.28  0.02
0.68  0.02 0.37  0.03
o 0.001 o 0.001
Table 3
Dose to the OARs according to the location of the tumor
V100% breast (%) V50% breast (%) V25% breast (%) V40% lung (%) V10% opp breast (%) V50% heart (%), n ¼ 22 V20% LAD (%), n ¼ 22
Inner quadrants (n ¼ 33)
Electron 1.6  0.3 12.4  1.2 17.0  1.5 4.1  0.6 0.0  0.0 0.3  0.1 24.5  5.7
Photon 1.9  0.5 17.3  1.9 34.4  2.0 4.0  0.6 11.0  2.5 1.9  0.7 29.6  6.6
p 0.462 0.001 o 0.001 0.854 o 0.001 0.018 0.273
Outer quadrants (n ¼ 39)
Electron 7.8  0.9 18.9  1.3 25.3  1.5 2.7  0.5 0.0  0.0 0.3  0.1 5.4  2.2
Photon 3.3  0.4 25.7  1.3 43.1  1.9 4.5  0.6 0.9  0.5 0.2  0.1 1.6  0.9
p o 0.001 o 0.001 o 0.001 0.007 o 0.105 0.639 0.097
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breast edema or skin atrophy was detected. It can be stated that
the relatively low rate of side effects in our study is owing to the
use of small-dose fractions and irradiated volumes. The length of
the follow-up time of this pilot study has been acceptable for the
consideration of both the efﬁcacy and the toxicity end points. For
the evaluation of the ﬁnal cosmetic outcome, nonetheless, a longer
observation of up to 10 to 15 years would be needed.
For APBI, the most common teletherapy regimen is 10 
3.85 Gy, 2 fractions per day.4 We used alternative fractionation,
with special regard to the high skin dose in case of electron
irradiation. Indeed, acute and late skin reactions were more
frequent in the electron arms, and we believe that the daily dose
of 3 Gy should not be exceeded if APBI is given with electron
beams. The advantages of electron and photon irradiation may
be simultaneously used in the mixed modality approach. In
certain PBI cases, the dose distribution and OAR exposure
may be optimized by the combination of photon and electron
ﬁelds.23-25
Only 1 contemporary study has reported the use of sole
electron ﬁelds for PBI.26,27 Altogether 40 patients with relatively
small breasts received electron irradiation of a dose of 25  2 Gy;
this technique resulted in the lowest rate (17.5%) of fat necrosis of
grade I to III, as compared with that in the brachytherapy and WBI
arms.26 None of our patients experienced symptomatic fat
necrosis, which may be a consequence of the surgical and radio-
therapy methods applied. In our experience, electron beams seemTable 4
Skin and breast changes according to treatment arm. Acute dermatitis was graded
at the end of the radiotherapy, whereas other side effects were evaluated Z1 year
thereafter
Photon Electron p, electron vs
photon
25  2 Gy,
n ¼ 18
13  3 Gy,
n ¼ 15
25  2 Gy,
n ¼ 19
13  3 Gy,
n ¼ 20
Acute dermatitis
Grade
I
2 (11.1%) 3 (20%) 11 (57.9%) 7 (35%) 0.001
Grade
II
0 (0%) 1 (6.7%) 2 (10.5%) 4 (20%)
Hyperpigmentation
Grade
I
0 (0%) 0 (0%) 3 (15.8%) 1 (5%) 0.095
Teleangiectasia
Grade
I
0 (0%) 0 (0%) 3 (15.8%) 4 (20%) 0.048
Subcutaneous/breast ﬁbrosis
Grade
I
0 (0%) 1 (6.7%) 0 (0%) 0 (0%) 0.408
Breast pain
Grade
I
2 (11.1%) 6 (40%) 4 (21%) 3 (15%) 0.273advantageous in approximately half of the cases with superﬁcial
and small PTVs, typical for inner-quadrant tumors.Conclusions
In everyday practice, for PBI, we recommend CRT with photons
or electrons according to the individual anatomic and geographic
situation of the tumor bed. The fractionation schedule of 13  3 Gy
seems as feasible as 25  2 Gy.References
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